Early detection of cerebral glucose uptake changes in the 5XFAD mouse

Current Alzheimer Research

Volumn 11, Issue 5, 2014, Pages 450-460

  Macdonald, I R ^a   DeBay, D R ^a,b   Reid, G A ^a   O'Leary, T P ^a   Jollymore, C T ^a   Mawko, G ^a   Burrell, S ^a   Martin, E ^c   Bowen, C V ^a,b   Brown, R E ^a   Darvesh, S ^a,c  

^a DALHOUSIE UNIVERSITY   (Canada)

^b IWK HEALTH CENTRE   (Canada)

^c MOUNT SAINT VINCENT UNIVERSITY   (Canada)

Author keywords

Alzheimer's disease; Computed tomography; Glucose metabolism; Magnetic resonance imaging; Positron emission tomography; Standardized uptake value; Tg6799; amyloid

Indexed keywords

AMYLOID BETA PROTEIN; BIOLOGICAL MARKER; FLUORODEOXYGLUCOSE F 18; GLUCOSE; AMYLOID PRECURSOR PROTEIN; PRESENILIN 1; PSEN1 PROTEIN, HUMAN;

5XFAD MOUSE; ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN REGION; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; FEMALE; GLUCOSE BRAIN LEVEL; GLUCOSE METABOLISM; GLUCOSE TRANSPORT; MOUSE; NEUROPATHOLOGY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SENILE PLAQUE; WILD TYPE; AGE; AMYLOID PLAQUE; ANIMAL; BRAIN; BRAIN CORTEX; COMPUTED TOMOGRAPHY SCANNER; DIAGNOSTIC USE; DISEASE MODEL; GENETICS; HUMAN; MALE; METABOLISM; MUTATION; PATHOLOGY; SCINTISCANNING; TRANSGENIC MOUSE;

AGE FACTORS; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; BRAIN; CEREBRAL CORTEX; DISEASE MODELS, ANIMAL; FEMALE; FLUORODEOXYGLUCOSE F18; GLUCOSE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MICE; MICE, TRANSGENIC; MUTATION; PLAQUE, AMYLOID; POSITRON-EMISSION TOMOGRAPHY; PRESENILIN-1; TOMOGRAPHY SCANNERS, X-RAY COMPUTED;

EID: 84904038822     PISSN: 15672050     EISSN: 18755828     Source Type: Journal    
DOI: 10.2174/1567205011666140505111354     Document Type: Article

References (39)

1. Huang Y, Mucke L. Alzheimer mechanisms and therapeutic strategies. Cell 148(6): 1204-22 (2012).
2. Li Y, Rinne JO, Mosconi L, Pirraglia E, Rusinek H, DeSanti S, et al. Regional analysis of FDG and PIB-PET images in normal aging, mild cognitive impairment, and Alzheimer's disease. Eur J Nucl Med Mol Imaging 35(12): 2169-81 (2008).
3. Chew J, Silverman DH. FDG-PET in early AD diagnosis. Med Clin North Am 97(3): 485-94 (2013).
4. Silverman DH, Small GW, Chang CY, Lu CS, Kung De Aburto MA, Chen W, et al. Positron emission tomography in evaluation of dementia: Regional brain metabolism and long-term outcome. JAMA 286(17): 2120-7 (2001).
5. Serrano-Pozo A, Frosch MP, Masliah E, Hyman BT. Neuropathological alterations in Alzheimer disease. Cold Spring Harb Perspect Med 1(1): a006189 (2011).
6. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297(5580): 353-6 (2002).
7. Oakley H, Cole SL, Logan S, Maus E, Shao P, Craft J, et al. Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer's disease mutations: potential factors in amyloid plaque formation. J Neurosci 26(40): 10129-40 (2006).
8. Reddy PH, Beal MF. Amyloid beta, mitochondrial dysfunction and synaptic damage: implications for cognitive decline in aging and Alzheimer's disease. Trends Mol Med 14(2): 45-53 (2008).
9. Reddy PH, Manczak M, Mao P, Calkins MJ, Reddy AP, Shirendeb U. Amyloid-beta and mitochondria in aging and Alzheimer's disease: implications for synaptic damage and cognitive decline. J Alzheimers Dis 20(2): S499-512 (2010).
10. Rojas S, Herance JR, Gispert JD, Abad S, Torrent E, Jimenez X, et al. In vivo evaluation of amyloid deposition and brain glucose metabolism of 5XFAD mice using positron emission tomography. Neurobiol Aging 34(7): 1790-8 (2013).
11. Reiman EM, Uecker A, Gonzalez-Lima F, Minear D, Chen K, Callaway NL, et al. Tracking Alzheimer's disease in transgenic mice using fluorodeoxyglucose autoradiography. Neuroreport 11(5): 987-91 (2000).
12. LaFerla FM, Green KN. Animal models of Alzheimer disease. Cold Spring Harb Perspect Med 2(11): 1-13 (2012).
13. Valla J, Gonzalez-Lima F, Reiman EM. FDG autoradiography reveals developmental and pathological effects of mutant amyloid in PDAPP transgenic mice. Int J Dev Neurosci 26(3-4): 253-8 (2008).
14. Valla J, Schneider L, Reiman EM. Age-and transgene-related changes in regional cerebral metabolism in PSAPP mice. Brain Res 1116(1): 194-200 (2006).
15. Kuntner C, Kesner AL, Bauer M, Kremslehner R, Wanek T, Mandler M, et al. Limitations of small animal PET imaging with [18F]FDDNP and FDG for quantitative studies in a transgenic mouse model of Alzheimer's disease. Mol Imaging Biol 11(4): 236-40 (2009).
16. Luo F, Rustay NR, Ebert U, Hradil VP, Cole TB, Llano DA, et al. Characterization of 7-and 19-month-old Tg2576 mice using multimodal in vivo imaging: limitations as a translatable model of Alzheimer's disease. Neurobiol Aging 33(5): 933-44 (2012).
17. Poisnel G, Herard AS, El Tannir El Tayara N, Bourrin E, Volk A, Kober F, et al. Increased regional cerebral glucose uptake in an APP/PS1 model of Alzheimer's disease. Neurobiol Aging 33(9): 1995-2005 (2012).
18. Dubois A, Herard AS, Delatour B, Hantraye P, Bonvento G, Dhenain M, et al. Detection by voxel-wise statistical analysis of significant changes in regional cerebral glucose uptake in an APP/PS1 transgenic mouse model of Alzheimer's disease. Neuroimage 51(2): 586-98 (2010).
19. Girard SD, Baranger K, Gauthier C, Jacquet M, Bernard A, Escoffier G, et al. Evidence for early cognitive impairment related to frontal cortex in the 5XFAD mouse model of Alzheimer's disease. J Alzheimers Dis 33(3): 781-96 (2013).
20. Eimer WA, Vassar R. Neuron loss in the 5XFAD mouse model of Alzheimer's disease correlates with intraneuronal Abeta42 accumulation and Caspase-3 activation. Mol Neurodegener 8: 2 (2013).
21. Macdonald IR, DeBay DR, Reid GA, O'Leary TP, Cash MK, Jollymore CT, et al. editors. Cerebral Glucose Metabolism, Pathology and Behaviour in the 5XFAD Mouse Model of Alzheimer's Disease. Alzheimer's Association International Conference 2013; 2013; Boston, MA.
22. Graham MM, Peterson LM, Hayward RM. Comparison of simplified quantitative analyses of FDG uptake. Nucl Med Biol 27(7): 647-55 (2000).
23. Ma Y, Hof PR, Grant SC, Blackband SJ, Bennett R, Slatest L, et al. A three-dimensional digital atlas database of the adult C57BL/6J mouse brain by magnetic resonance microscopy. Neurosci 135(4): 1203-15 (2005).
24. Ma Y, Smith D, Hof PR, Foerster B, Hamilton S, Blackband SJ, et al. In vivo 3D Digital Atlas Database of the Adult C57BL/6J Mouse Brain by Magnetic Resonance Microscopy. Front Neuroanat 2: 1 (2008).
25. Woods RP, Grafton ST, Holmes CJ, Cherry SR, Mazziotta JC. Automated image registration: I. General methods and intrasubject, intramodality validation. J Comput Assist Tomogr 22(1): 139-52 (1998).
26. Studholme C, Hill DL, Hawkes DJ. Automated 3-D registration of MR and CT images of the head. Med Image Anal 1(2): 163-75 (1996).
27. Loening AM, Gambhir SS. AMIDE: a free software tool for multimodality medical image analysis. Mol Imaging 2(3): 131-7 (2003).
28. Kitamoto T, Ogomori K, Tateishi J, Prusiner SB. Formic acid pretreatment enhances immunostaining of cerebral and systemic amyloids. Lab Invest 57(2): 230-6 (1987).
29. Jankowsky JL, Younkin LH, Gonzales V, Fadale DJ, Slunt HH, Lester HA, et al. Rodent A beta modulates the solubility and distribution of amyloid deposits in transgenic mice. J Biol Chem 282(31): 22707-20 (2007).
30. Shi Q, Prior M, He W, Tang X, Hu X, Yan R. Reduced amyloid deposition in mice overexpressing RTN3 is adversely affected by preformed dystrophic neurites. J Neurosci 29(29): 9163-73 (2009).
31. Paxinos G, Franklin K. The Mouse Brain in Stereotaxic Coordinates. 2nd ed. San Diego, CA: Academic Press; 2001.
32. Jawhar S, Trawicka A, Jenneckens C, Bayer TA, Wirths O. Motor deficits, neuron loss, and reduced anxiety coinciding with axonal degeneration and intraneuronal Abeta aggregation in the 5XFAD mouse model of Alzheimer's disease. Neurobiol Aging 33(1): 196 e29-40 (2012).
33. Mortimer JA. The Nun Study: risk factors for pathology and clinical-pathologic correlations. Curr Alzheimer Res 9(6): 621-7 (2012).
34. Reddy PH, McWeeney S, Park BS, Manczak M, Gutala RV, Partovi D, et al. Gene expression profiles of transcripts in amyloid precursor protein transgenic mice: up-regulation of mitochondrial metabolism and apoptotic genes is an early cellular change in Alzheimer's disease. Hum Mol Genet 13(12): 1225-40 (2004).
35. Manczak M, Anekonda TS, Henson E, Park BS, Quinn J, Reddy PH. Mitochondria are a direct site of A beta accumulation in Alzheimer's disease neurons: implications for free radical generation and oxidative damage in disease progression. Hum Mol Genet 15(9): 1437-49 (2006).
36. Bateman RJ, Xiong C, Benzinger TL, Fagan AM, Goate A, Fox NC, et al. Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med 367(9): 795-804 (2012).
37. Kikuchi T, Okamura T, Zhang MR, Irie T. PET probes for imaging brain acetylcholinesterase. Labelled Compounds and Radiopharmaceuticals 56: 172-9 (2013).
38. Darvesh S. Butyrylcholinesterase radioligands to image Alzheimer's disease brain. Chem Biol Interact 203(1): 354-7 (2013).
39. Britz-Cunningham SH, Millstine JW, Gerbaudo VH. Improved discrimination of benign and malignant lesions on FDG PET/CT, using comparative activity ratios to brain, basal ganglia, or cerebellum. Clin Nucl Med 33(10): 681-7 (2008).